Prothena Corporation plc Earnings

The next earnings date for Prothena Corporation plc is November 10, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Prothena Corporation plc Earnings

Report Date	Estimated Earnings Per Share
11/10/2025	$-0.54

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Prothena Corporation plc Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
08/07/2025	---	$-1.73	-41.86%
05/14/2025	After Market	$-1.12	-8.56%
02/10/2025	After Market	$-1.08	-3.74%
11/04/2024	After Market	$-1.10	6.78%
08/08/2024	After Market	$1.22	216.19%
05/08/2024	After Market	$-1.34	-11.67%
02/15/2024	After Market	$-1.26	-3.28%
11/02/2023	After Market	$0.38	218.75%
08/03/2023	After Market	$-1.03	-3.00%
05/04/2023	After Market	$-0.89	5.32%
02/23/2023	After Market	$0.12	125.53%
11/03/2022	After Market	$-0.97	-83.02%
08/08/2022	After Market	$-0.88	-69.23%
05/05/2022	After Market	$-0.78	-14.71%
02/17/2022	After Market	$-0.71	-22.41%
11/04/2021	After Market	$2.13	-6.58%
08/05/2021	After Market	$0.58	-42.00%
05/11/2021	After Market	$-0.91	-68.52%
02/11/2021	Before Market	$-0.77	0.00%
11/04/2020	After Market	$-0.77	-18.46%
08/06/2020	After Market	$-0.66	-8.20%
05/06/2020	After Market	$-0.59	-3.51%
02/12/2020	After Market	$-0.54	10.00%
11/05/2019	After Market	$-0.49	3.92%
08/06/2019	After Market	$-0.40	28.57%
05/07/2019	After Market	$-0.52	16.13%
02/14/2019	After Market	$-0.56	40.43%
11/06/2018	After Market	$-0.62	36.73%
08/07/2018	After Market	$-0.98	13.27%
05/08/2018	After Market	$-1.26	-46.51%
02/14/2018	After Market	$-1.24	16.22%
11/07/2017	After Market	$-1.37	1.44%
08/08/2017	After Market	$-0.46	47.73%
05/09/2017	After Market	$-0.99	28.78%
02/14/2017	After Market	$-1.41	-25.89%
11/01/2016	After Market	$-1.26	-3.28%
08/02/2016	After Market	$-1.18	-29.67%
05/03/2016	After Market	$-0.81	-5.19%
02/18/2016	After Market	$-0.76	6.17%
11/02/2015	After Market	$-0.73	-10.61%
08/04/2015	After Market	$-0.59	-5.36%
05/05/2015	After Market	$-0.55	6.78%
03/05/2015	After Market	$-0.48	27.27%
11/03/2014	After Market	$-0.48	20.00%
08/04/2014	---	$0.06	142.86%
05/05/2014	---	$0.78	0.00%
03/06/2014	---	$-0.52	-4.00%
11/12/2013	---	$-0.55	16.67%
08/12/2013	---	$-0.64	-23.08%
05/29/2013	---	$-0.51	---
03/29/2013	---	$-0.84	---

More About Prothena Corporation plc

Website

https://www.prothena.com

Country

USA

Full Time Employees

163

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

“Prothena Corporation plc Earnings” Can Refer to the Prothena Corporation plc Earnings Date

Some people say “Prothena Corporation plc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Prothena Corporation plc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Prothena Corporation plc Stock on the Earnings Date

If you own Prothena Corporation plc stock (PRTA) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Prothena Corporation plc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Prothena Corporation plc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Prothena Corporation plc Earnings

You can contact us any time if you would like to ask questions about Prothena Corporation plc earnings or anything else related to the stock market.